Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer (TARSEQ)

• Free survival at 12 months [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
• Toxicities and feasibility [ Time Frame: 15 Weeks ] [ Designated as safety issue: Yes ]
  To assess toxicities and feasibility in both groups

This 2 arms study will compare the efficacy and safety of treatment with sequential erlotinib plus docetaxel therapy versus docetaxel alone as second line treatment in patients with recurrent non-small cell lung cancer. Patients will be randomized to receive in group 1(experimental arm): docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16 and group 2 (control arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.

The anticipated time on study treatment is until disease progression. Target sample size is 156.

The main of this study is to determine the relevance of the association sequential erlotinib and docetaxel in terms of progression-free survival .

In this study, the patient will be randomized in group 1(experimental arm): docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16 and group 2 (control arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.

Assessment during treatment: Physical examination, ECG,: every 3 weeks, laboratory tests: weekly, every 3 weeks pulmonary X-ray .The CT scans:. Measurable targets are assessed by RECIST compared to the beginning of treatment: at 6 weeks (day 42 EVA 2), 12 weeks (D84 EVA 3), 15 weeks (D105 EVA 4: Evaluation of the SSP) and then every 6 weeks until progression.

Quality of life will be assessed Day 42 then every 6 weeks during chemotherapy, Tolerability will be assessed at each visit based on CTC v4.0 criteria.

• Drug: Erlotinib + docetaxel
  docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
• Drug: Docetaxel
  docetaxel :75 mg/m² IV day 1 every 3 weeks.

• Active Comparator: Docetaxel
  Intervention: Drug: Docetaxel
• Experimental: Erlotinib
  Intervention: Drug: Erlotinib + docetaxel

Inclusion Criteria:

• Histologically proven NSCLC (
• Mutational status of EGFR : wild type or unknown
• Stage IV disease with cytologic or histologic documentation in patients with a single easily accessible metastasis or metastatic relapses in a non irradiated region from a primary tumor treated with surgery or radiotherapy (with cytologic or histologic documentation of relapse)
• Presence of at least one measurable target lesion (one dimension) in a non irradiated region (at least 10 mm on spiral computed tomography).
• Age ≥ 18 years
• Performance status 0,1,2 exception : age > 74 years only PS 0 or 1
• Normal hepatic function
• Normal renal function
• Normal calcemia
• Normal haematological function
• Life expectancy > 12 weeks.
• Women of child bearing potential must use effective contraception.
• Men might be surgically sterile or accept to use an effective contraceptive procedure during and until 6 months after the treatment.
• Written informed consent to participate in the study.

Exclusion Criteria:

• PS > 2, exception : age > 74 years only PS ≥ 2
• Presence of another cancer
• Previous treatment with an anti egfr agent or docetaxel
• QT prolongation (>470 ms)
• Uncontrolled arterial hypertension.
• Concurrent radiotherapy, except for palliative bone irradiation.
• Stroke less than 6 months before study entry.
• Psychiatric or neurological disorders preventing the patient from understanding the nature of the trial
• Uncontrolled infection.
• Caval syndrome
• Other organic disorders preventing inclusion in the trial
• Malabsorption syndrome
• Allergy to erlotinib or one of its constituents
• Allergy to docetaxel or one of its constituents
• Pregnancy and breast-feeding
• Surgery less than two months before study entry